Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v4-EN
Language French English
Date Updated 2021-10-25 2021-10-25
Drug Identification Number 02046709 02046709
Brand name CLINIMIX CLINIMIX
Common or Proper name CLINIMIX 5% Amino Acids (Blend B) in 16.6% Dextrose Injection CLINIMIX 5% Amino Acids (Blend B) in 16.6% Dextrose Injection
Company Name BAXTER CORPORATION BAXTER CORPORATION
Ingredients L-ISOLEUCINE L-LYSINE METHIONINE L-PHENYLALANINE HYDROCHLORIDE L-LEUCINE HYDROCHLORIDE DEXTROSE L-TYROSINE L-PROLINE L-ARGININE GLYCINE L-ALANINE TRYPTOPHAN L-THREONINE HISTIDINE L-VALINE L-ISOLEUCINE L-LYSINE METHIONINE L-PHENYLALANINE HYDROCHLORIDE L-LEUCINE HYDROCHLORIDE DEXTROSE L-TYROSINE L-PROLINE L-ARGININE GLYCINE L-ALANINE TRYPTOPHAN L-THREONINE HISTIDINE L-VALINE
Strength(s) 240MG 290MG 290MG 310MG 310MG 16.6G 20MG 210MG 520MG 1040MG 1040MG 90MG 210MG 220MG 230MG 240MG 290MG 290MG 310MG 310MG 16.6G 20MG 210MG 520MG 1040MG 1040MG 90MG 210MG 220MG 230MG
Dosage form(s) LIQUID LIQUID
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 1000mL (JB6770P) 1000mL (JB6770P)
ATC code B05BA B05BA
ATC description I.V. SOLUTIONS I.V. SOLUTIONS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2021-10-13 2021-10-13
Actual start date 2021-10-13 2021-10-13
Estimated end date 2021-10-21 2021-10-21
Actual end date 2021-10-21 2021-10-21
Shortage status Resolved Resolved
Tier 3 Status No No
Company comments Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order. Baxter is experiencing a delay in raw materials which has resulted in a supply disruption on certain CLINIMIX and TRAVASOL products. Impacted products have been placed on allocation. The supply issue is expected to be resolved in early October. Contact your Baxter sales rep or Baxter customer service for list of available CLINIMIX products which remain available to order.
Health Canada comments